- Home
- ZURA vs LUNG Comparison
ZURA vs LUNG Comparison
Compare ZURA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- LUNG
- Stock Information
- Founded
- ZURA 2022
- LUNG 1995
- Country
- ZURA United States
- LUNG United States
- Employees
- ZURA N/A
- LUNG N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- ZURA Health Care
- LUNG Health Care
- Exchange
- ZURA Nasdaq
- LUNG Nasdaq
- Market Cap
- ZURA 292.1M
- LUNG 290.8M
- IPO Year
- ZURA N/A
- LUNG 2020
- Fundamental
- Price
- ZURA $4.47
- LUNG $7.21
- Analyst Decision
- ZURA Buy
- LUNG Strong Buy
- Analyst Count
- ZURA 6
- LUNG 6
- Target Price
- ZURA $15.80
- LUNG $13.83
- AVG Volume (30 Days)
- ZURA 357.4K
- LUNG 233.0K
- Earning Date
- ZURA 11-07-2024
- LUNG 10-30-2024
- Dividend Yield
- ZURA N/A
- LUNG N/A
- EPS Growth
- ZURA N/A
- LUNG N/A
- EPS
- ZURA N/A
- LUNG N/A
- Revenue
- ZURA N/A
- LUNG $79,302,000.00
- Revenue This Year
- ZURA N/A
- LUNG $22.73
- Revenue Next Year
- ZURA N/A
- LUNG $19.02
- P/E Ratio
- ZURA N/A
- LUNG N/A
- Revenue Growth
- ZURA N/A
- LUNG 22.34
- 52 Week Low
- ZURA $2.00
- LUNG $5.46
- 52 Week High
- ZURA $6.35
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- ZURA 55.38
- LUNG 60.38
- Support Level
- ZURA $4.00
- LUNG $7.21
- Resistance Level
- ZURA $4.85
- LUNG $7.82
- Average True Range (ATR)
- ZURA 0.26
- LUNG 0.46
- MACD
- ZURA -0.01
- LUNG 0.17
- Stochastic Oscillator
- ZURA 68.13
- LUNG 89.62
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.